Danaher Corporation (DHR)

NYSE: DHR · Real-Time Price · USD

209.06

-1.86 (-0.88%)

At close: Oct 17, 2025, 4:00 PM EDT

208.40

-0.66 (-0.32%)

After-hours: Oct 17, 2025, 7:54 PM EDT

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Jun '25 Jun 27, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Biotechnology Revenue	6.98B	6.76B	Log In	Log In	Log In	Upgrade
Life Sciences Revenue	7.27B	7.33B	Log In	Log In	Log In	Upgrade
Former Life Sciences Revenue	14.26B	14.09B	Log In	Log In	Log In	Upgrade
Diagnostics Revenue	9.76B	9.79B	Log In	Log In	Log In	Upgrade
Environmental & Applied Solutions Revenue	-	-	Log In	Log In	Log In	Upgrade
Revenue (Other)	-14.26B	-14.09B	Log In	Log In	Log In	Upgrade
Revenue (Total)	24.01B	23.88B	Log In	Log In	Log In	Upgrade

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Jun '25 Jun 27, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
North America Revenue	10.25B	10.30B	Log In	Log In	Log In	Upgrade
Western Europe Revenue	5.66B	5.46B	Log In	Log In	Log In	Upgrade
Other Developed Markets Revenue	1.23B	1.25B	Log In	Log In	Log In	Upgrade
High-Growth Markets Revenue	6.87B	6.87B	Log In	Log In	Log In	Upgrade
Revenue (Total)	24.01B	23.88B	Log In	Log In	Log In	Upgrade

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Jun '25 Jun 27, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Recurring Revenue	19.67B	19.37B	Log In	Log In	Log In	Upgrade
Non-Recurring Revenue	4.35B	4.51B	Log In	Log In	Log In	Upgrade
Revenue (Total)	24.01B	23.88B	Log In	Log In	Log In	Upgrade

EBIT

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Jun '25 Jun 27, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Biotechnology Operating Income	1.87B	1.69B	Log In	Log In	Log In	Upgrade
Life Sciences Operating Income	373.00M	879.00M	Log In	Log In	Log In	Upgrade
Former Life Sciences Operating Income	2.24B	2.56B	Log In	Log In	Log In	Upgrade
Diagnostics Operating Income	2.51B	2.63B	Log In	Log In	Log In	Upgrade
Environmental & Applied Solutions Operating Income	-	-	Log In	Log In	Log In	Upgrade
Operating Income (Other)	-337.00M	-326.00M	Log In	Log In	Log In	Upgrade
Operating Income (Total)	4.42B	4.86B	Log In	Log In	Log In	Upgrade

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Jun '25 Jun 27, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Core Sales Growth Ex-Cytiva	-	-	Log In	Log In	Log In	Upgrade
Core Sales Growth	-	-1.50%	Log In	Log In	Log In	Upgrade

Updated Jul 22, 2025. Data Source: Fiscal.ai.